<DOC>
	<DOCNO>NCT01500226</DOCNO>
	<brief_summary>This Phase 3 , multicenter , randomize , parallel-group , double-blind , active-controlled study rolapitant subject receive MEC . Rolapitant placebo administer prior initiation chemotherapy Day 1 granisetron dexamethasone . Subjects record event emesis use rescue medication establish nausea and/or vomiting , indicate severity nausea experience previous 24 hour Nausea Vomiting ( NV ) Subject Diary prior MEC administration Day 6 Cycle 1 . Health-related quality life measure FLIE Questionnaire Day 6 Cycle 1 . Safety tolerability assess clinical review adverse event ( AEs ) , physical examination , electrocardiogram ( ECGs ) , safety laboratory value . All subject expect complete Cycle 1 option participate five additional cycle .</brief_summary>
	<brief_title>Ph 3 Safety/Efficacy Study Rolapitant Prevention CINV Subjects Receiving Moderately Emetogenic Chemotherapy</brief_title>
	<detailed_description>This Phase 3 , multicenter , randomize , parallel-group , double-blind , active-controlled study rolapitant subject receive MEC . Rolapitant placebo administer orally 1-2 hour prior initiation chemotherapy Day 1 . Granisetron ( 2 mg PO ) dexamethasone ( 20 mg PO ) administer approximately 30 minute initiation chemotherapy . Subjects continue receive granisetron ( 2 mg daily ) Days 2 3 . Subjects record event emesis use rescue medication establish nausea and/or vomiting , indicate severity nausea experience previous 24 hour Nausea Vomiting ( NV ) Subject Diary prior MEC administration Day 6 Cycle 1 . Health-related quality life measure FLIE Questionnaire Day 6 Cycle 1 . Safety tolerability assess clinical review adverse event ( AEs ) , physical neurological examination , vital sign , electrocardiogram ( ECGs ) , safety laboratory value include BUN creatinine . All subject expect complete Cycle 1 option participate five additional cycle . Blood sample may collect store study may analyze future biomarker research relate safety efficacy .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>8- ( ( 1- ( 3,5-bis ( trifluoromethyl ) phenyl ) ethoxy ) methyl ) -8-phenyl-1,7-diazaspiro ( 4,5 ) decan-2-one</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>18 year age old , either gender , race Naïve moderately highly emetogenic chemotherapy , receive first course MEC include one follow agent : cyclophosphamide IV ( &lt; 1500 mg/m2 ) , doxorubicin , epirubicin , carboplatin , idarubicin , ifosfamide , irinotecan , daunorubicin , cytarabine IV ( &gt; 1 g/m2 ) . Karnofsky performance score ≥60 Predicted life expectancy ≥4 month Adequate bone marrow , kidney , liver function Contraindication administration prescribe MEC agent , granisetron , dexamethasone Is pregnant breast feeding Has take follow agent within last 48 hour 5HT3 antagonist , Phenothiazines , Benzamides , Domperidone , Cannabinoids , NK1 antagonist , Benzodiazepines Scheduled receive chemotherapeutic agent emetogenicity level 3 ( Hesketh Scale ) Day 2 Day 6 , except Day 1 Scheduled receive radiation therapy abdomen pelvis Day 5 Day 6 Has receive systemic corticosteroid sedative antihistamine within 72 hour Day 1 study except premedication chemotherapy ( e.g. , taxanes ) Symptomatic primary metastatic CNS disease . Has ongoing vomiting , retch , clinically significant nausea cause etiology , history anticipatory nausea vomit . Has vomit and/or dry heaves/retching within 24 hour prior start MECon Day 1 Cycle 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Rolapitant</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>CINV</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>